Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Pegram

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Clinical Breast Cancer|September 10, 2008
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?Mark Pegram
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Intratumoral HER2 heterogeneity in breast cancerMark Pegram
Oncology (Williston Park, N.Y.)|June 21, 2013
Treatment combinations for HER2-positive breast cancerMark Pegram
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Breast cancer: review of platinum-based cooperative group trialsMark Pegram
Cancer Drug Resistance (Alhambra, Calif.)|December 10, 2021
Research advances and new challenges in overcoming triple-negative breast cancerYu Zong, Mark Pegram
Breast Cancer Research and Treatment|July 19, 2003
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapyJohn Crown, Mark Pegram
Advanced Drug Delivery Reviews|August 1, 2006
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case studyMark Pegram, Debbie Ngo
Breast Cancer Research and Treatment|October 17, 2009
Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?Kazuhiro Araki, Mark Pegram
Reviews in Endocrine & Metabolic Disorders|September 28, 2007
HER2 targeted therapy in breast cancer...beyond HerceptinSumanta Kumar Pal, Mark Pegram
Anti-Cancer Drugs|April 23, 2005
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapySumanta Kumar Pal, Mark Pegram
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Clinical Breast Cancer|September 10, 2008
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?Mark Pegram
Clinical Advances in Hematology & Oncology : H&O|October 2, 2020
Intratumoral HER2 heterogeneity in breast cancerMark Pegram
Oncology (Williston Park, N.Y.)|June 21, 2013
Treatment combinations for HER2-positive breast cancerMark Pegram
Journal of the National Comprehensive Cancer Network : JNCCN|September 29, 2009
Breast cancer: review of platinum-based cooperative group trialsMark Pegram
Cancer Drug Resistance (Alhambra, Calif.)|December 10, 2021
Research advances and new challenges in overcoming triple-negative breast cancerYu Zong, Mark Pegram
Breast Cancer Research and Treatment|July 19, 2003
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapyJohn Crown, Mark Pegram
Advanced Drug Delivery Reviews|August 1, 2006
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case studyMark Pegram, Debbie Ngo
Breast Cancer Research and Treatment|October 17, 2009
Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?Kazuhiro Araki, Mark Pegram
Reviews in Endocrine & Metabolic Disorders|September 28, 2007
HER2 targeted therapy in breast cancer...beyond HerceptinSumanta Kumar Pal, Mark Pegram
Anti-Cancer Drugs|April 23, 2005
Epidermal growth factor receptor and signal transduction: potential targets for anti-cancer therapySumanta Kumar Pal, Mark Pegram
Pageof 7